Key clinical point: Next-generation sequencing revealed therapeutically actionable molecular alterations in patients with relapsed/refractory cancers.
Major finding: In all, 37.6% of patients had actionable alterations, and 17.8% were assigned to targeted treatment.
Study details: The phase 2 NCI-MATCH trial included 5,954 cancer patients from 1,117 sites.
Disclosures: NCI-MATCH was funded by the National Cancer Institute. The authors disclosed relationships with many companies.
Flaherty KT et al. J Clin Oncol. 2020 Oct 13. doi: 10.1200/JCO.19.03010.